Janssen Pharmaceuticals Inc.

11/11/2019 | Press release | Distributed by Public on 11/11/2019 17:14

TREMFYA® (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, Meets Primary Endpoints of Superior ACR20 Responses versus Placebo at Week 24 in Phase 3 Psoriatic[...]